OSI-420 - CAS 183320-51-6
Catalog number: B0084-286627
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
OSI-420 (CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for the inhibition of human EGFR and EGFR autophosphorylation in tumor cells.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-286627 10 mg $198 In stock
B0084-286627 50 mg $598 In stock
Bulk Inquiry
OSI-420; CP-473420; Desmethyl Erlotinib.
For research used only
Canonical SMILES:
1.A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
Svedberg A1, Gréen H2, Vikström A3, Lundeberg J4, Vikingsson S5. J Pharm Biomed Anal. 2015 Mar 25;107:186-95. doi: 10.1016/j.jpba.2014.12.022. Epub 2014 Dec 25.
A liquid chromatography tandem mass spectrometry method was developed and validated for quantification of erlotinib and its metabolites in human plasma. The method is suitable for therapeutic drug monitoring and pharmacokinetic studies. The substances were extracted using protein precipitation, separated on a BEH XBridge C18 column (100 ×2.1 mm, 1.7 μm) by gradient elution at 0.7 mL/min of acetonitrile and 5 mM ammonium acetate. The concentration was determined using a Waters Xevo triple quadrupole mass spectrometer in a multi reaction monitoring mode. The total run time was 7 min. Deuterated erlotinib and OSI-597 were used as internal standard for erlotinib and its metabolites, respectively. Erlotinib, OSI-420 and didesmethyl erlotinib were quantified in the concentration range 25-5000 ng/mL, 0.5-500 ng/mL and 0.15-10 ng/mL, respectively. Precision and accuracy was <14% except for OSI-420 at LLOQ (17%). Extraction recovery was above 89%, 99% and 89% for erlotinib, OSI-420 and didesmethyl erlotinib, respectively.
2.A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
Macpherson IR1, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TR. Eur J Cancer. 2013 Mar;49(4):782-9. doi: 10.1016/j.ejca.2012.09.036. Epub 2012 Oct 22.
AIM: To determine the maximum tolerated dose (MTD) of OSI-930 that can be combined with erlotinib, and establish recommended phase 2 doses when both agents are administered daily in patients with advanced solid tumours.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products

CAS 807640-87-5 JNJ-26483327

(CAS: 807640-87-5)

JNJ-26483327 is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted...

CAS 122520-85-8 AG 99

AG 99
(CAS: 122520-85-8)

AG 99, an EGF receptor tyrosine kinase inhibitor, has been found to show activities in diagnosis, prevention and treatment of cancer.

PKI 166 hydrochloride

PKI 166 is a potent EGFR-kinase inhibitor (IC50 = 0.7 nM), with >3000-fold selectivity against a panel of serine/threonine kinases. PKI 166 potently inhibits th...

(CAS: 1275595-86-2)

Selatinib is a Epidermal growth factor receptor(EGFR) and ERbB-2 receptor antagonist as an analog of the quinazoline lapatinib with potential antineoplastic act...

(CAS: 1448232-80-1)

Naquotinib is an irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity wit...

CAS 937265-83-3 ARRY-380

(CAS: 937265-83-3)

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

(CAS: 936446-61-6)

NRC-2694 is a small molecule antagonist of epidermal growth factor receptor (EGFR) signalling pathways, for the treatment of solid tumors.

(CAS: 413599-62-9)

ZD-4190, a substituted 4-anilinoquinazoline, is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of e...

CAS 1110813-31-4 Dacomitinib

(CAS: 1110813-31-4)

Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the p...

CAS 1421373-65-0 AZD-9291

(CAS: 1421373-65-0)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

CAS 1375465-09-0 CNX-2006

(CAS: 1375465-09-0)

CNX-2006 is a potent and mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbourin...

CAS 881001-19-0 HDS 029

HDS 029
(CAS: 881001-19-0)

HDS 029 is a potent inhibitor of the ErbB receptor family including EGFR, ErbB2 and ErbB4 (IC50 = 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2, respect...

CAS 1035638-91-5 PF 6274484

PF 6274484
(CAS: 1035638-91-5)

PF 6274484 is a high affinity and potent covalent EGFR kinase inhibitor (Ki = 0.14 nM). It inhibits the autophosphorylation of wild-type EGFR in A549 cells and ...

(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

CAS 1050500-29-2 AST-1306

(CAS: 1050500-29-2)

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-ove...

CAS 497839-62-0 AEE-788

(CAS: 497839-62-0)

AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth facto...

CAS 63177-57-1 Methyl 2,5-dihydroxycinnamate

Methyl 2,5-dihydroxycinnamate
(CAS: 63177-57-1)

Methyl 2,5-dihydroxycinnamate, a stable analog of erbstatin, is a stable, potent inhibitor of EGFR kinase activity. It is described to be four-times more stable...

CAS 133550-41-1 AG 556

AG 556
(CAS: 133550-41-1)

AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...

(CAS: 1903008-80-9)

Lazertinib, also known as YH-25448 and GNS-1480, is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible 3rd gene...

CAS 1374640-70-6 Rociletinib

(CAS: 1374640-70-6)

Rociletinib is a third-generation irreversible kinase inhibitor of epidermal growth factor receptor (EGFR). Rociletinib was shown to inhibit the proliferation o...

Chemical Structure

CAS 183320-51-6 OSI-420

Quick Inquiry

Verification code

Featured Items